Pair Name | Quercitrin, Insulin | ||
Phytochemical Name | Quercitrin (PubChem CID: 5280459 ) | ||
Anticancer drug Name | Insulin (PubChem CID: 16131098 ) | ||
Structure of Phytochemical |
Download
2D
MOL
3D
MOL
|
||
Structure of Anticancer Drug |
Download
2D
MOL
3D
MOL
|
Pair Name | Quercitrin, Insulin | |||
Disease Info | [ICD-11: 5A80] | Polycystic ovary syndrome | Investigative | |
Gene Regulation | Up-regulation | Phosphorylation | AKT1 | hsa207 |
Up-regulation | Phosphorylation | MTOR | hsa2475 | |
Up-regulation | Phosphorylation | PIK3CA | hsa5290 | |
Up-regulation | Expression | PM20D1 | hsa148811 | |
Up-regulation | Phosphorylation | PRKAA1 | hsa5562 | |
In Vitro Model | 3T3-L1 | Healthy | Mus musculus (Mouse) | CVCL_0123 |
In Vivo Model | A total of 48 (specific pathogen-free) SPF female Sprague Dawley rats (aged from six weeks, body weight of 130 –150 g) were uesd in study. | |||
Result | PM20D1 and PI3K/Akt were required for lipolysis and endocrine regulation in PCOS-IR to restore ovarian function and maintain normal endocrine metabolism. By upregulating the expression of PM20D1, quercitrin activated the PI3K/Akt signaling pathway, improved adipocyte catabolism, corrected reproductive and metabolic abnormalities, and had a therapeutic effect on PCOS-IR. |
No. | Title | Href |
---|---|---|
1 | Quercitrin alleviates lipid metabolism disorder in polycystic ovary syndrome-insulin resistance by upregulating PM20D1 in the PI3K/Akt pathway. Phytomedicine. 2023 Aug;117:154908. doi: 10.1016/j.phymed.2023.154908. | Click |